Strike Pharma

Precision therapy through antibody conjugation. Cell-specific delivery of nucleotide-based drugs is achieved using a novel technology for affinity conjugation of nanoparticles to antibodies. Two distinct drug development platforms are developed: 40fy is a platform for enhancing efficacy of LNP-based cancer vaccines through CD40-conjugation, while isiCAR-T builds on selective delivery of LNP-based vectors to T-cells. STR3/19 is a preclinical drug development in situ CAR-T candidate that reprograms T-cells inside the body with the aim to attack CD19-expressing B cells in lymphoma.